In addition to the shared variants, MT-ND5 also presents a high rate of exclusive variants not only in tumor samples but also in internal control samples, suggesting that this gene could also be altered in cells in other adjacent organs of cancer patients, contributing to possible tumor advances. This evidence concerns the gene MT-ND5 and cancer.